Targeting inflammation in diabetic nephropathy: a tale of hope.

Targeting inflammation in diabetic nephropathy: a tale of hope. Expert Opin Investig Drugs. 2018 Oct 18;: Authors: Moreno JA, Gomez-Guerrero C, Mas S, Sanz AB, Lorenzo O, Ruiz-Ortega M, Opazo L, Mezzano S, Egido J Abstract INTRODUCTION: Diabetic nephropathy (DN) is the leading cause of chronic kidney disease (CKD) and end stage renal disease (ESRD). Beyond the new anti-diabetic drugs that possess markedly cardiovascular and renal protective effects, no novel direct therapies for DN have become available on the market in the last twenty years. Recently well-designed clinical trials for the treatment of DN, with attractive pathogenetic rationale, e.g. bardoxolone and atrasentan, were cancelled or stopped because of safety concerns or lack of reaching the end-points, respectively. Areas covered: In this review we focus on the involvement of inflammation in the pathogenesis of DN. We update information from recent experimental and clinical studies that reported beneficial effects of several agents targeting chemokines, cytokines, transcription factors and kinases as well as several compounds with anti-inflammatory properties on DN. Expert opinion: Inflammation plays a key role on the DN progression. Preclinical studies have identified several anti-inflammatory molecules that effective decrease albuminuria and/or proteinuria. However, limited clinical trials in humans have been performed to confirm these results. Inhibitors of CCL2/CCR2, ...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research